摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-chloro-3-(2,2-dimethoxyethylamino)quinoxaline | 191349-68-5

中文名称
——
中文别名
——
英文名称
2-chloro-3-(2,2-dimethoxyethylamino)quinoxaline
英文别名
3-chloro-N-(2,2-dimethoxyethyl)quinoxalin-2-amine
2-chloro-3-(2,2-dimethoxyethylamino)quinoxaline化学式
CAS
191349-68-5
化学式
C12H14ClN3O2
mdl
——
分子量
267.715
InChiKey
VPDLDNPQNDDZSK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    18
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    56.3
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Imidazo[1,2-a]quinoxalin-4-amines: A novel class of nonxanthine A1-adenosine receptor antagonists
    摘要:
    The syntheses and A(1) adenosine receptor affinities of a number of imidazo[1,2-alpha]quinoxalin-4-amines are reported. Structure activity relationships within the series and in comparison with other similar tricyclic nonxanthine adenosine antagonists are discussed, leading to a putative common binding mode of these nitrogen-containing heterocycles to A(1) adenosine receptors. Secondary amino compounds displayed the best affinities toward A(1) receptors, while the tertiary amines were almost devoid of activity, thus suggesting a crucial role for the hydrogen bond-forming 4-NH group. Remarkably higher potencies for l-methyl and N-cyclopentyl derivatives were also found. 4-Cyclopentylamino-1-methylimidazo[1,2-alpha]quinoxaline (IRFI 165) is the most potent compound in this series, having K-i(A(1)) = 7.9 nM. It is also provided with a good A(1) selectivity both versus A(2a) and A(3) subtypes and was selected for further pharmacological studies. (C) Elsevier, Paris.
    DOI:
    10.1016/s0223-5234(99)80019-1
  • 作为产物:
    描述:
    2,3-二氯喹喔啉氨基乙醛缩二甲醇乙醇 为溶剂, 以50 %的产率得到2-chloro-3-(2,2-dimethoxyethylamino)quinoxaline
    参考文献:
    名称:
    咪唑[1,2-a]喹喔啉衍生物作为针对植物病原真菌的潜在抗真菌剂的合成和评价
    摘要:
    为了发现新颖有效的潜在农业抗真菌剂,设计了各种咪唑[1,2-a]喹喔啉衍生物,并用现有和廉价的试剂合成。首先针对 10 种典型的植物病原真菌评估了它们的抗真菌活性。体外抗真菌活性表明,一些化合物比两种市售杀菌剂百菌清和噻沙唑表现出更明显的广谱杀菌活性。Mali 和 Botrytis cinerea 菌株对 10 多种化合物的 EC50 值为 1.4-27.0 μg/mL,表现出最高的敏感性。化合物 5c 和 5f 分别对苹果笙草 (EC50 = 5.6 μg/mL) 和茄子镰刀菌 (EC50 = 5.1 μg/mL) 显示出最有希望的抑制作用。关于作用机制的初步研究表明,咪唑[1,2-a]喹喔啉骨架可能通过破坏菌丝分化、孢子萌发和胚芽管生长来发挥其抗真菌作用。此外,细胞实验结果表明,这些靶标化合物对 BV2 细胞具有良好的安全性。总体而言,化合物 5c 和 5f 可以被认为是针对特定真菌的
    DOI:
    10.1007/s11030-023-10739-y
点击查看最新优质反应信息

文献信息

  • US6124287
    申请人:——
    公开号:——
    公开(公告)日:——
  • US06124287
    申请人:——
    公开号:——
    公开(公告)日:——
  • IMIDAZO[1,2-a]QUINOXALIN-4-AMINES ACTIVE AS ADENOSINE ANTAGONISTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
    申请人:Biomedica Foscama Industria Chimico-Farmaceutica S.p.A.
    公开号:EP0865442B1
    公开(公告)日:2000-07-05
  • US6124287A
    申请人:——
    公开号:US6124287A
    公开(公告)日:2000-09-26
  • Imidazo[1,2-a]quinoxalin-4-amines: A novel class of nonxanthine A1-adenosine receptor antagonists
    作者:Stefano Ceccarelli、Alessandra D'Alessandro、Michela Prinzivalli、Sergio Zanarella
    DOI:10.1016/s0223-5234(99)80019-1
    日期:1998.12
    The syntheses and A(1) adenosine receptor affinities of a number of imidazo[1,2-alpha]quinoxalin-4-amines are reported. Structure activity relationships within the series and in comparison with other similar tricyclic nonxanthine adenosine antagonists are discussed, leading to a putative common binding mode of these nitrogen-containing heterocycles to A(1) adenosine receptors. Secondary amino compounds displayed the best affinities toward A(1) receptors, while the tertiary amines were almost devoid of activity, thus suggesting a crucial role for the hydrogen bond-forming 4-NH group. Remarkably higher potencies for l-methyl and N-cyclopentyl derivatives were also found. 4-Cyclopentylamino-1-methylimidazo[1,2-alpha]quinoxaline (IRFI 165) is the most potent compound in this series, having K-i(A(1)) = 7.9 nM. It is also provided with a good A(1) selectivity both versus A(2a) and A(3) subtypes and was selected for further pharmacological studies. (C) Elsevier, Paris.
查看更多